Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in USD (TTM)37.81bn
- Net income in USD13.23bn
- Incorporated1931
- Employees71.88k
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
- Websitehttps://www.novonordisk.com/
Mergers & acquisitions
| Acquired company | NOVO B:CPH since announced | Transaction value |
|---|---|---|
| Cardior Pharmaceuticals GmbH | -15.61% | 1.11bn |
| Catalent Inc-Manufacturing Sites Portfolio(3) | -4.18% | -- |
| Elan Drug Technologies (DNU>16Sep2011 now 01781A) | 11.45% | 92.42m |
| Alkermes PLC-Development & Manufacturing Facility | 11.45% | 92.50m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 9.15bn | 2.43bn | 79.84bn | 14.10k | 33.27 | 15.27 | 27.17 | 8.72 | 5.32 | 5.32 | 20.02 | 11.59 | 0.6431 | 1.06 | 6.86 | 649,078.00 | 17.13 | 14.47 | 19.38 | 17.18 | 70.13 | 69.77 | 26.64 | 25.77 | 2.27 | 18.96 | 0.5567 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 28.30bn | 126.00m | 112.40bn | 18.00k | 1,073.82 | 6.08 | 39.06 | 3.97 | 0.084 | 0.084 | 22.61 | 14.83 | 0.4842 | 3.56 | 6.04 | 1,572,167.00 | 0.1933 | 6.74 | 0.242 | 8.12 | 77.80 | 79.14 | 0.3993 | 16.95 | 1.10 | 17.00 | 0.5584 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 47.44bn | -7.26bn | 119.40bn | 34.10k | -- | 6.96 | 40.65 | 2.52 | -3.60 | -3.60 | 23.38 | 8.45 | 0.513 | 3.97 | 5.12 | 1,391,056.00 | -7.84 | 3.05 | -10.45 | 3.76 | 75.87 | 76.13 | -15.28 | 7.69 | 1.09 | 11.30 | 0.7431 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Pfizer Inc | 60.11bn | 4.27bn | 145.36bn | 88.00k | 34.48 | 1.57 | 12.98 | 2.42 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 32.53bn | 4.23bn | 158.32bn | 26.70k | 37.69 | 21.03 | 16.15 | 4.87 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Merck & Co Inc | 63.17bn | 12.15bn | 250.89bn | 72.00k | 20.80 | 5.64 | 15.27 | 3.97 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.53bn | 5.08bn | 312.70bn | 50.00k | 61.73 | 51.84 | 23.14 | 5.63 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Novo Nordisk A/S (ADR) | 37.81bn | 13.23bn | 357.53bn | 71.88k | 35.47 | 27.56 | 24.65 | 9.46 | 2.96 | 2.96 | 8.46 | 3.81 | 0.7758 | 1.23 | 4.55 | 596,611.80 | 27.16 | 29.17 | 59.83 | 58.62 | 84.66 | 83.93 | 35.01 | 33.55 | 0.7546 | -- | 0.321 | 50.13 | 31.26 | 15.74 | 50.71 | 16.72 | 25.67 | 10.97 |
| Johnson & Johnson | 87.70bn | 14.77bn | 373.59bn | 131.90k | 25.51 | 5.32 | 16.94 | 4.26 | 6.08 | 6.05 | 36.12 | 29.14 | 0.5094 | 2.27 | 5.66 | 664,867.30 | 8.58 | 8.93 | 11.90 | 11.96 | 69.16 | 68.17 | 16.84 | 18.86 | 0.7853 | -- | 0.3376 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 30 Sep 2024 | 20.20m | 0.60% |
| Fisher Asset Management LLCas of 30 Sep 2024 | 13.31m | 0.39% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 12.74m | 0.38% |
| Fayez Sarofim & Co.as of 30 Sep 2024 | 12.22m | 0.36% |
| Folketrygdfondetas of 30 Sep 2024 | 8.86m | 0.26% |
| Loomis, Sayles & Co. LPas of 30 Sep 2024 | 8.62m | 0.25% |
| Managed Account Advisors LLCas of 30 Sep 2024 | 8.28m | 0.24% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 8.19m | 0.24% |
| GQG Partners LLCas of 30 Sep 2024 | 7.44m | 0.22% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 6.96m | 0.21% |
